CN102138911B - 一种双丙戊酸钠缓释片及其制备方法 - Google Patents
一种双丙戊酸钠缓释片及其制备方法 Download PDFInfo
- Publication number
- CN102138911B CN102138911B CN2011100756373A CN201110075637A CN102138911B CN 102138911 B CN102138911 B CN 102138911B CN 2011100756373 A CN2011100756373 A CN 2011100756373A CN 201110075637 A CN201110075637 A CN 201110075637A CN 102138911 B CN102138911 B CN 102138911B
- Authority
- CN
- China
- Prior art keywords
- divalproex sodium
- preparation
- tablet
- release
- slow releasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 title claims abstract description 44
- 229940028937 divalproex sodium Drugs 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title abstract description 33
- 239000007939 sustained release tablet Substances 0.000 title abstract description 11
- 239000000203 mixture Substances 0.000 claims description 24
- 239000011230 binding agent Substances 0.000 abstract description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 239000000314 lubricant Substances 0.000 abstract description 5
- 239000003085 diluting agent Substances 0.000 abstract description 3
- 238000013268 sustained release Methods 0.000 abstract description 2
- 239000012730 sustained-release form Substances 0.000 abstract description 2
- 230000000181 anti-adherent effect Effects 0.000 abstract 1
- 239000003911 antiadherent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000003340 retarding agent Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 40
- 239000003814 drug Substances 0.000 description 31
- 238000000034 method Methods 0.000 description 23
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 16
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 10
- 229920002125 Sokalan® Polymers 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 238000005469 granulation Methods 0.000 description 10
- 230000003179 granulation Effects 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229960001631 carbomer Drugs 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229960004756 ethanol Drugs 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 238000005550 wet granulation Methods 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 3
- 230000001037 epileptic effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- -1 valproate ion Chemical class 0.000 description 3
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229940082484 carbomer-934 Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 229940084026 sodium valproate Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940031663 carbomer-974p Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100756373A CN102138911B (zh) | 2011-03-28 | 2011-03-28 | 一种双丙戊酸钠缓释片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100756373A CN102138911B (zh) | 2011-03-28 | 2011-03-28 | 一种双丙戊酸钠缓释片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102138911A CN102138911A (zh) | 2011-08-03 |
CN102138911B true CN102138911B (zh) | 2012-12-12 |
Family
ID=44406856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100756373A Active CN102138911B (zh) | 2011-03-28 | 2011-03-28 | 一种双丙戊酸钠缓释片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102138911B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103230380B (zh) * | 2013-05-06 | 2015-02-18 | 北京四环制药有限公司 | 双丙戊酸钠肠溶片芯及其制备方法和其应用 |
CN104146976B (zh) * | 2014-08-06 | 2017-02-15 | 沈阳药科大学 | 一种高负载丙戊酸类药物缓释片及其制备方法 |
CN106389368B (zh) * | 2015-07-29 | 2021-11-12 | 四川科瑞德制药股份有限公司 | 一种丙戊酸钠缓释制剂及其制备工艺和用途 |
CN107028907B (zh) * | 2016-02-04 | 2021-05-14 | 成都康弘药业集团股份有限公司 | 一种双丙戊酸钠缓释片 |
CN107811985B (zh) * | 2016-09-13 | 2021-05-28 | 四川科瑞德制药股份有限公司 | 一种抗癫痫缓释制剂及其制备方法与用途 |
CN109674758A (zh) * | 2019-02-25 | 2019-04-26 | 湖南博隽生物医药有限公司 | 一种用于治疗癫痫的双丙戊酸钠缓释片及其制备方法 |
CN113304117B (zh) * | 2021-04-30 | 2023-05-12 | 山东京卫制药有限公司 | 一种丙戊酸钠缓释片的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1335769A (zh) * | 1998-12-18 | 2002-02-13 | 艾博特公司 | 双丙戊酸钠的控释制剂 |
CN1921838A (zh) * | 2004-02-19 | 2007-02-28 | 兰贝克赛实验室有限公司 | 双丙戊酸钠的缓释药物组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1671363A (zh) * | 2002-06-07 | 2005-09-21 | 兰贝克赛实验室有限公司 | 二丙戊酸钠的缓释制剂 |
-
2011
- 2011-03-28 CN CN2011100756373A patent/CN102138911B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1335769A (zh) * | 1998-12-18 | 2002-02-13 | 艾博特公司 | 双丙戊酸钠的控释制剂 |
CN1921838A (zh) * | 2004-02-19 | 2007-02-28 | 兰贝克赛实验室有限公司 | 双丙戊酸钠的缓释药物组合物 |
Non-Patent Citations (1)
Title |
---|
YIHONG QIU et al.Once-a-Day Controlled-Release Dosage Form of Divalproex Sodium I: Formulation Design and In Vitro/In Vivo Investigations.《JOURNAL OF PHARMACEUTICAL SCIENCES》.2003,第92卷(第6期),1167页"实验"部分至1172页"结果及讨论"部分. |
Also Published As
Publication number | Publication date |
---|---|
CN102138911A (zh) | 2011-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102138911B (zh) | 一种双丙戊酸钠缓释片及其制备方法 | |
EP2777696B1 (en) | Preparation of stable pharmaceutical dosage forms | |
CN102579381B (zh) | 盐酸胍法辛缓释制剂及其制备方法 | |
CN102091051B (zh) | 一种别嘌醇双释放制剂及其制备方法 | |
CN101851247B (zh) | 含有硫酸氢氯吡格雷晶体颗粒的组合物 | |
CN101810628B (zh) | 二甲双胍格列吡嗪片及其制备方法 | |
CN105434386B (zh) | 一种含有高水溶性活性成分的缓释片剂及其制备方法 | |
CN102755301B (zh) | 格列美脲组合物片及其制备方法 | |
CN103263395A (zh) | 一种替米沙坦片剂及其制备方法 | |
CN104546732A (zh) | 一种右旋布洛芬缓释片及其制备工艺 | |
WO2013189305A1 (zh) | 缬沙坦氨氯地平复方固体制剂及其制备方法 | |
CN102764254B (zh) | 一种左乙拉西坦药物组合物及其制备方法 | |
CN101342177B (zh) | 氯诺昔康双层缓释片 | |
CN102846573A (zh) | 水飞蓟宾双层缓释片及其制备方法 | |
CN103655504B (zh) | 右旋酮洛芬氨丁三醇速释缓释双层片及其制备工艺 | |
CN111617048B (zh) | 一种用于治疗非小细胞肺癌的厄洛替尼缓释制剂 | |
CN101940560A (zh) | 一种盐酸米诺环素缓释片及其不同规格的制备方法 | |
CN103371981A (zh) | 一种含瑞格列奈和盐酸二甲双胍的复方固体速释制剂及其制备方法和用途 | |
CN103565766A (zh) | 一种美沙拉秦肠溶缓释片 | |
RU2441651C1 (ru) | Способ получения фармацевтической композиции клозапина в виде таблеток и фармацевтическая композиция | |
CN101244068B (zh) | 雪胆素缓释制剂 | |
CN106727375B (zh) | 阿戈美拉汀片剂及其制备方法 | |
CN111249246A (zh) | 一种左乙拉西坦缓释片剂及其制备方法 | |
CN109700773B (zh) | 一种替格瑞洛制剂组合物及其制备方法 | |
CN103142527A (zh) | 恩替卡韦钾片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHONGSHUAI PHARMACEUTICAL SCIENCE AND TECHNOLOGY I Free format text: FORMER OWNER: SUN WEIDONG Effective date: 20140123 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140123 Address after: 18, A1, 7, Holly Street, 450001 hi tech Zone, Henan, Zhengzhou Patentee after: ZHONGSHUAI PHARMACEUTICAL SCI & TECH INCORPORATED CO., LTD. Address before: 18, building 7, building A, bio Pharmaceutical Industrial Park, 450001 Holly Road, Gaoxin District, Henan, Zhengzhou Patentee before: Sun Weidong |